Bedaquiline: A Promising new agent for the treatment of MDR-TB

Tuberculosis (TB) remains the single most infectious disease causing the highest mortality in humans. India is the highest TB burden country according to World Health Organization (WHO) statistics for 2011. The previous studies in India showed that 3% of multi drug resistant TB (MDR-TB) is seen in new tuberculosis cases and 17.2% among retreatment cases. The alarming increase in MDR-TB and the emergence of extensively drug resistant TB(XDR-TB) are man-made snags; therefore new drugs for the treatment of drug-resistant tuberculosis are obligatory.On 28thDecember 2012, the U.S. Food and Drug Administration approved bedaquiline (TMC207), as part of combination therapy to treat adults with MDR-TB when other alternatives are not available. Bedaquiline, a diarylquinoline has a unique mechanism of action and acts as a promising new agent in patients with MDR-TB.

Author(s): Jyoti M. Benni

Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+
30+ Million Readerbase
Recommended Conferences
Flyer image
Abstracted/Indexed in
  • Google Scholar
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Directory of Research Journal Indexing (DRJI)
  • WorldCat
  • Publons
  • MIAR
  • ResearchGate
  • University Grants Commission
  • Secret Search Engine Labs


tempobet giriş

tempobet giriş

tipobet süpertotobet yeni adres süperbahis 747 güvenilir bahis siteleri telefonda sex sohbet